These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

620 related items for PubMed ID: 27096719

  • 1. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors.
    Abdulrezzak U, Kurt YK, Kula M, Tutus A.
    Nucl Med Commun; 2016 Aug; 37(8):874-81. PubMed ID: 27096719
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E, Alshammari A, Michopoulou S, Skoura E, Naik K, Maragkoudakis E, Mohmaduvesh M, Al-Harbi M, Belda M, Caplin ME, Toumpanakis C, Bomanji J.
    J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. 18F-FDG PET/CT Volumetric Parameters are Associated with Tumor Grade and Metastasis in Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease.
    Satoh K, Sadowski SM, Dieckmann W, Quezado M, Nilubol N, Kebebew E, Patel D.
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):714-721. PubMed ID: 27638678
    [Abstract] [Full Text] [Related]

  • 6. Dual Somatostatin Receptor/18F-FDG PET/CT Imaging in Patients with Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors.
    Metser U, Nunez JE, Chan D, Kulanthaivelu R, Murad V, Santiago AT, Singh S.
    J Nucl Med; 2024 Oct 01; 65(10):1591-1596. PubMed ID: 39266292
    [Abstract] [Full Text] [Related]

  • 7. Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy.
    Zhang J, Liu Q, Singh A, Schuchardt C, Kulkarni HR, Baum RP.
    J Nucl Med; 2020 Nov 01; 61(11):1560-1569. PubMed ID: 32169914
    [Abstract] [Full Text] [Related]

  • 8. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
    Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ.
    Cancer; 2008 Jun 01; 112(11):2447-55. PubMed ID: 18383518
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
    Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, Warwitz B, Gerardo L, Henninger B, Virgolini I, Rodrigues M.
    Eur J Nucl Med Mol Imaging; 2016 Aug 01; 43(9):1585-92. PubMed ID: 26922350
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A prospective head-to-head comparison of 68 Ga-NOTA-3P-TATE-RGD and 68 Ga-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours.
    Jiang Y, Liu Q, Wang G, Sui H, Wang R, Wang J, Zhu Z.
    Eur J Nucl Med Mol Imaging; 2022 Oct 01; 49(12):4218-4227. PubMed ID: 35657429
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D, Kuyumcu S, Turkmen C, Sanlı Y, Aykan F, Unal S, Adalet I.
    J Nucl Med; 2014 Nov 01; 55(11):1811-7. PubMed ID: 25315243
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
    Werner RA, Weich A, Higuchi T, Schmid JS, Schirbel A, Lassmann M, Wild V, Rudelius M, Kudlich T, Herrmann K, Scheurlen M, Buck AK, Kropf S, Wester HJ, Lapa C.
    Theranostics; 2017 Nov 01; 7(6):1489-1498. PubMed ID: 28529632
    [Abstract] [Full Text] [Related]

  • 20. 68Ga-DOTA-TATE PET/CT for Molecular Imaging of Somatostatin Receptor Expression in Metastasizing Chordoma: Comparison With 18F-FDG.
    Derlin T, Sohns JM, Hueper K.
    Clin Nucl Med; 2017 Apr 01; 42(4):e210-e211. PubMed ID: 28166150
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.